Surgical Oncology Insight最新文献

{"title":"Travel distance does not affect overall survival in patients with appendiceal adenocarcinoma undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","authors":"Javid Sadjadi,&nbsp;Li Luo,&nbsp;Bridget Fahy,&nbsp;Vinay K. Rai,&nbsp;Sarah Popek,&nbsp;Lara Baste McKean,&nbsp;Alissa Greenbaum","doi":"10.1016/j.soi.2024.100068","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100068","url":null,"abstract":"<div><h3>Introduction</h3><p>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a potentially curative approach for appendiceal cancer (AC) with peritoneal dissemination and is most often employed at tertiary referral centers. Regionalization may provide geographic barriers to care for vulnerable patients. The aim of this study was to examine the effect of travel distance on oncologic outcomes of patients with AC treated with CRS-HIPEC.</p></div><div><h3>Methods</h3><p>The National Cancer Database (NCDB) was reviewed from 2006 through 2020 for patients with AC who underwent CRS-HIPEC. The primary comparison variable was distance (&lt;50 miles vs ≥ 50 miles from the CRS-HIPEC facility). Demographic and tumor characteristics were analyzed. Primary outcome was overall survival (OS). Secondary outcomes were 30-day and 90-day mortality, readmission, and length of stay (LOS).</p></div><div><h3>Results</h3><p>During the study period, 1703 patients met inclusion criteria, with 1000 patients travelling &lt; 50 miles for CRS-HIPEC (59 %) and 703 travelling ≥ 50 miles (41 %). Patients who traveled ≥ 50 miles were more likely to be non-Hispanic White (p &lt; 0.001), have annual income less than $74,062, be treated at an academic center and live in the South-Atlantic region of the United States. There was no significant difference in OS between groups (Figure 1). There were no significant differences in 30-day postoperative survival, 90-day survival, or 30-day readmission. Post-operative LOS was 8.0 versus 9.0 days (p &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>Travel distance ≥ 50 miles was not significantly associated with decreased OS or increased postoperative mortality, suggesting that regionalization of care does not worsen oncologic outcomes for patients with AC undergoing CRS-HIPEC.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S295024702400077X/pdfft?md5=e1085278b10eea3c2cfb0cd01b11bfb6&pid=1-s2.0-S295024702400077X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141595656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disaggregating U.S. Asian and Pacific Islanders: Colorectal cancer","authors":"Ian Chun ,&nbsp;Brenda Y. Hernandez ,&nbsp;Hyeong Jun Ahn ,&nbsp;Christina Wai","doi":"10.1016/j.soi.2024.100066","DOIUrl":"10.1016/j.soi.2024.100066","url":null,"abstract":"<div><h3>Background</h3><p>Colorectal cancer remains a public health concern as the 4th most common cancer in the US. Incidence and mortality have been observed to differ between races; however, Asian and Pacific Islander ethnicities are often documented in aggregate. Recognizing that these groups are heterogeneous, this study seeks to disaggregate Native Hawaiian from the broader “Asian/Pacific Islander” group and examine disparate outcomes in colorectal cancer.</p></div><div><h3>Methods</h3><p>De-identified data from the Hawaii Tumor Registry was queried to evaluate colorectal cancer in the state of Hawaii. Primary outcomes were cancer stage at diagnosis, first course of therapies received, and duration of survival from diagnosis. Chi-square analyses were performed for differences in categorical variables.</p></div><div><h3>Results</h3><p>7943 Hawaii residents were diagnosed with colorectal cancer in 2008–2018 with 1151 (14.5 %) patients identifying as Native Hawaiian. Native Hawaiians were less likely to present with localized cancer (36.7 % vs. 41.7 %; p = 0.002) and more likely to be diagnosed with distant stage cancer compared to non-Native Hawaiians (25.2 % vs. 17.67 %; p &lt; 0.0001) and, among those with distant metastases, more likely to receive chemotherapy (68.3 % vs. 61.1 %; p = 0.029). No significant differences were observed between races on analysis of CRC-specific mortality.</p></div><div><h3>Conclusion</h3><p>Significant differences exist between disaggregated Asian and Pacific Islander ethnic groups. Native Hawaiians are observed to present with more advanced cancer at the time of diagnosis in comparison to ethnicities. Disaggregating these groups reveals racial and ethnic disparities that may inform public health measures.</p></div><div><h3>Synopsis</h3><p>Disaggregating Asian and Native Hawaiian and Pacific Islander groups reveals disparities in colorectal cancer. Native Hawaiians presented with more advanced disease across all studied ethnic groups. No significant differences were observed in colorectal cancer specific mortality across groups.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000756/pdfft?md5=5e7a842a5568527a0ed648b29a9dbc8c&pid=1-s2.0-S2950247024000756-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141408090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interference with activities of daily living according to pain level after breast surgery","authors":"Kate R. Pawloski ,&nbsp;Su Hnin ,&nbsp;Hannah L. Kalvin ,&nbsp;Varadan Sevilimedu ,&nbsp;Tiana Le ,&nbsp;Audree B. Tadros ,&nbsp;Laurie J. Kirstein ,&nbsp;Monica Morrow ,&nbsp;Tracy-Ann Moo","doi":"10.1016/j.soi.2024.100067","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100067","url":null,"abstract":"<div><h3>Background</h3><p>The degree to which postoperative pain interferes with activities of daily living (ADLs) after breast surgery is unclear. We assessed the effect of pain on interference and analgesic use following lumpectomy and sentinel lymph node biopsy (lump-SLNB), and mastectomy.</p></div><div><h3>Methods</h3><p>We retrospectively identified consecutive patients who completed ≥1 post-discharge survey(s) on postoperative days (POD) 1–5 (lump-SLNB) and 1–10 (mastectomy) from 1/2019–12/2020. The highest pain score was used to categorize none/mild and moderate/severe pain groups. Interference was reported as “none/a little”, “somewhat”, and “quite a bit/very much”. Two-sample non-parametric tests compared baseline characteristics.</p></div><div><h3>Results</h3><p>1067 patients underwent lump-SLNB; 1219 underwent mastectomy—436 (41%) and 857 (70%) patients reported moderate/severe pain, of whom 190 (44%) and 121 (14%) rated interference as “none/a little”, 178 (41%) and 341 (40%) as “somewhat”, and 68 (16%) and 395 (46%) as “quite a bit/very much”, respectively. Patients with moderate/severe pain more frequently reported “quite a bit/very much” interference versus those with none/mild pain (lump-SLNB: 16% versus 1.1%, p&lt;0.001; mastectomy: 46% versus 3.8%, p&lt;0.001). Compared to POD1, the proportion of patients with the highest degree of interference declined on each subsequent POD in both surgical cohorts. Following mastectomy, median opioid use was 2 pills overall, and 6 pills for the highest interference group.</p></div><div><h3>Conclusions</h3><p>Interference was more common in patients with moderate/severe pain; however, postmastectomy opioid use was low regardless of interference level. Our findings can inform expectations regarding postoperative pain, interference, and the feasibility of opioid-sparing recovery pathways.</p></div><div><h3>Synopsis</h3><p>Patients with moderate/severe pain after breast surgery experience more interference compared to those with none/mild pain. Postmastectomy opioid use is low, including patients reporting higher interference; most patients experience an early return to baseline function regardless of pain level.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000768/pdfft?md5=4cda19debadb8f1205899d675af08e24&pid=1-s2.0-S2950247024000768-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141322700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and survival of Extramammary Paget’s Disease from the Surveillance, Epidemiology, and End Results (SEER) database","authors":"Edouard H. Nicaise ,&nbsp;Maeve McNamara ,&nbsp;Benjamin N. Schmeusser ,&nbsp;Gregory Palmateer ,&nbsp;Dattatraya Patil ,&nbsp;John Petros ,&nbsp;Philippe E. Spiess ,&nbsp;Andrea Necchi ,&nbsp;Kenneth Ogan ,&nbsp;Keith A. Delman ,&nbsp;Viraj A. Master","doi":"10.1016/j.soi.2024.100064","DOIUrl":"10.1016/j.soi.2024.100064","url":null,"abstract":"<div><h3>Background</h3><p>Extramammary Paget’s Disease (EMPD) is a rare intraepithelial neoplasm that often presents in anogenital regions, primarily affecting older, female, and Asian patients. Clinical progression is insidious, with delay in diagnosis up to years common. This study sought to investigate contemporary trends in incidence and survival across sexes.</p></div><div><h3>Methods</h3><p>Retrospective review of EMPD patients in 22 SEER registries from 2004 to 2020. Cases were categorized by primary disease site. Additional data included race, sex, ethnicity, age, disease stage, treatment type, and time to treatment. Age-adjusted incidence rates were calculated from 2000 to 2020. Kaplan-Meier curves estimated survival and univariable and multivariable Cox proportional hazards models examined factors associated with all-cause mortality.</p></div><div><h3>Results</h3><p>3608 patients were included: 1179 male and 2429 female. 76.2 % of patients had documented treatment with 32.4 % experiencing a 3 + month delay. Incidence was greatest among Asian patients, with a rate 2x greater than white patients, however, the APC was only significant among white patients (+1.22 %). Ten-year survival estimate was 63.0 % in female patients versus 53.4 % in male patients (p &lt; 0.001). On multivariable analysis, older age, advanced stage, and treatment delay were associated with worsened overall survival, while surgery alone decreased the risk of mortality in comparison to no cancer-directed treatment.</p></div><div><h3>Conclusions</h3><p>Over the past 20 years, the incidence of EMPD has risen across sexes, with survival significantly worsened by older age, advanced stage, and delay in treatment. In addition, primary surgical treatment, when performed early with complete resection, may decrease the long-term mortality risk.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000732/pdfft?md5=b81376864097fb3735da2ad330430d1a&pid=1-s2.0-S2950247024000732-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141410383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a bloodless medicine program on pancreatic resections: A single-institution experience incorporating patients with borderline-resectable and locally advanced pancreatic cancer","authors":"Gabriel D. Ivey ,&nbsp;Julia Purchla ,&nbsp;Nicolas C. Cruz ,&nbsp;Ananda Thomas ,&nbsp;Thomas J. McPhaul ,&nbsp;Christopher R. Shubert ,&nbsp;Kelly J. Lafaro ,&nbsp;Richard A. Burkhart ,&nbsp;John L. Cameron ,&nbsp;Jin He ,&nbsp;Steven M. Frank ,&nbsp;William R. Burns","doi":"10.1016/j.soi.2024.100065","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100065","url":null,"abstract":"<div><h3>Background</h3><p>Patients undergoing pancreatic resection who decline blood transfusion represent a clinical challenge. While bloodless medicine programs are valuable, their impact remains unclear, especially for those with borderline-resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).</p></div><div><h3>Methods</h3><p>Retrospective review of institutional databases identified patients who did not accept blood transfusion and underwent pancreatic resection from 2013–2022. We collated hemoglobin values, interventions to minimize symptomatic anemia, and patient outcomes.</p></div><div><h3>Results</h3><p>Thirteen patients were identified. Median age was 63 years (range: 52–75 years) and eight (61.5 %) were female. All procedures were performed electively for invasive malignancy with PDAC as the most common diagnosis (11/13; 84.6 %) and pancreaticoduodenectomy as the most common procedure (11/13; 84.6 %). Vascular involvement was common in the 11 patients with PDAC (borderline-resectable: 7/11; 63.6 % and locally advanced: 3/11; 27.3 %), as was the use of multi-agent chemotherapy (n = 10) and preoperative radiotherapy (n = 8) prior to surgery. Median blood loss was 400 mL (range: 100–2200 mL). Intraoperative measures included acute normovolemic hemodilution in one patient and red blood cell salvage in three patients. Median preoperative hemoglobin was 12.3 g/dL (range: 10.3–14.2 g/dL) and median nadir hemoglobin was 9.2 g/dL (range: 5.2–11.8 g/dL). Median hospital stay was 10 days (range: 6–42 days). Thirty-day mortality was 0 % and one-year overall survival was 69.2 % with median follow-up of 26.4 months.</p></div><div><h3>Conclusion</h3><p>Pancreatic resections can be performed safely in patients who decline blood transfusion, even with borderline-resectable and locally advanced PDAC. Avoiding transfusions and employing blood-conservation techniques does not appear to detrimentally impact survival.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000744/pdfft?md5=1f16ecb3f86784aa69ded03ef5fdc121&pid=1-s2.0-S2950247024000744-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141329009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally invasive training in surgical oncology: Current status and needs assessment","authors":"","doi":"10.1016/j.soi.2024.100063","DOIUrl":"10.1016/j.soi.2024.100063","url":null,"abstract":"<div><p>Utilization of minimally invasive surgery (MIS) has grown significantly over the past three decades, changing the face of surgical oncology practice. Changes to educational programming have been more scattered. Surgical training has undergone a major transformation with duty hour restrictions, decreased autonomy, and increased technology in the workplace. Despite increasing exposure to laparoscopic and robotic approaches, there is a lack of standardized training in residency, fellowship and beyond. As a result, surgeons report feeling ill-equipped for independent MIS oncology practice. While long term data is limited, several models of MIS curriculum implementation exist in gastrointestinal, hepato-pancreatico-biliary, and colorectal surgery. The aim of this review is to describe the current state of robotic training in surgical oncology and offer directions for future research and practice.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000720/pdfft?md5=7ccf40af5b5b4c8461ff633ac6255b5c&pid=1-s2.0-S2950247024000720-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141278629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of locoregional therapy in gastric cancer with peritoneal metastasis","authors":"Ankur Tiwari ,&nbsp;Katiuscha Merath ,&nbsp;Sukeshi Patel Arora ,&nbsp;Alexander Parikh ,&nbsp;Mio Kitano ,&nbsp;Colin M. Court","doi":"10.1016/j.soi.2024.100056","DOIUrl":"10.1016/j.soi.2024.100056","url":null,"abstract":"<div><p>The peritoneum is a common site of early dissemination of gastric cancer (GC) as well as a common site of recurrence after curative gastrectomy. Peritoneal metastasis (PM) is a major cause of morbidity and mortality in patients with GC and is associated with poor prognosis, making treatment of peritoneal disease is an important target for improving survival. The development of standardized methods to assess extent of peritoneal disease, an increased understanding of intraperitoneal chemotherapy, and improvements in systemic chemotherapy have renewed interest in the curative-intent treatment of GCPM. The different approaches of locoregional therapy for GCPM includes surgical resection, intraperitoneal chemotherapy, and a combination of the two. Surgical resection involves gastrectomy and/or a cytoreductive surgery (CRS) with removal of all visible disease. Intraperitoneal (IP) chemotherapy can involve administering heated chemotherapy usually at the time of surgery i.e., Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or laparoscopically in the neoadjuvant setting i.e., NL-HIPEC, chemotherapy given immediately post-op i.e., Early Post-operative Intraperitoneal Chemotherapy (EPIC), multiple infusions of non-heated chemotherapy i.e. Normothermic Intraperitoneal Chemotherapy Long Term (NIPEC-LT) or the newer technique of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). This review provides an overview of these different locoregional treatment modalities and summarizes the evolution of the techniques, regimens, and applications of IP chemotherapy. It highlights the multitude of options available, the promising yet heterogenous existing literature and the exciting ongoing work that will hopefully help establish the role of locoregional therapy in GCPM.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000653/pdfft?md5=5b3cafc1bb2b0147e10331765fdbe90d&pid=1-s2.0-S2950247024000653-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141042235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the use of nipple sparing mastectomy: A review of the indications and techniques","authors":"Nathan V. Doremus ,&nbsp;Kevin Vega ,&nbsp;Michael G. Tecce ,&nbsp;Suhail Kanchwala","doi":"10.1016/j.soi.2024.100062","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100062","url":null,"abstract":"<div><p>The nipple sparing mastectomy (NSM) has allowed for targeted tumor extirpation while maintaining the breast skin envelope and nipple-areola complex. Initially, the indications for this reconstructive technique were quite narrow, but ongoing investigation have expanded the indications and safety profile of the NSM from an oncologic and reconstructive standpoint. Historically, patients with elevated body mass index, macromastia, high-grade ptosis, and ongoing tobacco use were deemed high-risk candidates for ischemic complications. Development and utilization of numerous techniques have allowed the NSM to be offered more frequently to these high-risk candidates. Specifically, many methods including single-stage and multi-stage/delay techniques have been developed for the patient with high-grade ptosis.</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000719/pdfft?md5=77f048828ed1f5969c9a1ab3cb4a2ddc&pid=1-s2.0-S2950247024000719-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141303839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum [Surgical Oncology Insight, volume 1 (2024)]","authors":"","doi":"10.1016/j.soi.2024.100060","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100060","url":null,"abstract":"","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000690/pdfft?md5=a503ff56789bf9565ef5a26e9596b005&pid=1-s2.0-S2950247024000690-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141164531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features and short-term surgical outcomes of early-onset versus late-onset colorectal cancer at a tertiary hospital in Tanzania: A retrospective-cohort study","authors":"George Kanani ,&nbsp;Samwel Byabato ,&nbsp;Jasmine Mrisho ,&nbsp;Vihar Kotecha ,&nbsp;Yasin Munis ,&nbsp;Felician Kachinde ,&nbsp;Ahmed Binde","doi":"10.1016/j.soi.2024.100061","DOIUrl":"https://doi.org/10.1016/j.soi.2024.100061","url":null,"abstract":"<div><h3>Background</h3><p>Despite the reported rising trend of early-onset CRC incidence globally, little is known about the clinical profile and primary CRC surgical outcome in Tanzania and sub-Saharan Africa. This study aimed to analyze the clinicopathological features and short-term surgical outcomes of early-onset CRC patients undergoing primary surgery.</p></div><div><h3>Methodology</h3><p>The patients who underwent primary CRC surgery and whose diagnosis was confirmed by histopathology were identified and reviewed from prospectively maintained medical records. Clinicopathological characteristics and short-term surgical outcomes were analyzed and compared between groups.</p></div><div><h3>Results</h3><p>A total of 225 patients were included in this study, there were 137 patients in the late-onset CRC group and 88 in the early-onset group. After a 1:1 ratio PSM, there were 86 patients in each group. The overall proportion of early-onset CRC patients was 39.1 %. With regards to baseline characteristics of gender, tumor stage, tumor location, and presenting symptoms, there was no significant difference between early-onset and late-onset CRC patient groups before and after propensity score Matching (PSM) analysis (p &gt; 0.05). After PSM, Early-onset CRC patients had a significantly higher proportion of Signet-ring cell histology (p = 0.007) and a higher rate of overall postoperative complications, (p = 0.043). The multivariate analyses showed that early-onset CRC patients (p = 0.048, OR=2.14, 95 % CI=1.01–4.53) and emergency surgery (p = 0.011, OR=2.79, 95 % CI=1.27–6.13) were significant predictors of overall postoperative complications</p></div><div><h3>Conclusion</h3><p>Early-onset CRC patients showed a significantly higher proportion of Signet-ring cell histology (poorly differentiated) and overall short-term postoperative complications. The early-onset CRC patients and emergency surgery were significant predictors of overall short-term postoperative complications</p></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950247024000707/pdfft?md5=596cae09279b2b2c8bb33d39dee4f07f&pid=1-s2.0-S2950247024000707-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141264108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}